Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for VAX-31 (PCV Infant) in Invasive pneumococcal disease. The expected timing is based on the latest available company guidance and may change.
11/12/24- IND cleared. 12/3/24- Ph2 initiated. 2/5/25- Advanced to second stage. 8/6/25- Discontinue Low-dose arm, add Optimized dose arm, topline data in H1 2027. 11/04/25:- Infant Ph2 advanced to third final stage; topline data still expected H1 2027. 12/08/25:- Infant Ph2 topline data from primary series and booster still expected by H1 2027 end. 01/22/26:- Infant Ph2 dose-finding study NCT06720038 fully enrolled; topline series and booster data by H1 2027 end. 02/24/26:- Enrollment of 900 infants completed; topline primary series and booster data expected by end of H1 2027. 05/06/26:- Infant VAX-31 Ph2 enrollment reiterated; primary and booster topline data still expected by end of H1 2027. 08/05/26:- Infant Ph2 primary and booster topline data reiterated by end H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.